Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424
Menopause01:28

Menopause

3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new, ultra-stable lab for nano-metrology of x-ray optics at Diamond Light Source.

The Review of scientific instruments·2025
Same author

Socioeconomic and ethnic disparities in preterm births in an English maternity setting: a population-based study of 1.3 million births.

BMC medicine·2024
Same author

Tamoxifen evolution.

British journal of cancer·2023
Same author

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes.

Immunotherapy advances·2022
Same author

The impact of the COVID-19 pandemic on UK medical education. A nationwide student survey.

Medical teacher·2021
Same author

Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2021
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.2K

Antiestrogens: future prospects

A Howell1

  • 1Christie Hospital N.H.S. Trust, Department of Medical Oncology, Manchester, United Kingdom.

Oncology (Williston Park, N.Y.)
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

New antiestrogen therapies are being developed to improve upon tamoxifen for breast cancer treatment. These agents show promise with enhanced estrogen receptor binding and antitumor activity compared to tamoxifen.

More Related Videos

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation
09:49

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Published on: October 31, 2019

23.1K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.8K

Related Experiment Videos

Last Updated: Jan 9, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.2K
Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation
09:49

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Published on: October 31, 2019

23.1K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Tamoxifen is the standard endocrine therapy for early and advanced breast cancer.
  • Research is ongoing to develop more effective antiestrogen therapies.
  • Improving therapeutic efficacy is a key goal in breast cancer treatment.

Purpose of the Study:

  • To review novel antiestrogen compounds.
  • To compare their efficacy with tamoxifen.
  • To discuss preclinical and clinical data of these agents.

Main Methods:

  • Review of existing literature on antiestrogen compounds.
  • Comparison of preclinical and clinical data.
  • Analysis of estrogen-receptor binding affinity and antitumor activity.

Main Results:

  • Several novel nonsteroidal and steroidal antiestrogens have been developed.
  • Some agents demonstrate improved estrogen-receptor binding affinity.
  • Enhanced antiestrogenic and antitumor activity compared to tamoxifen is observed in some compounds.

Conclusions:

  • New antiestrogen agents offer potential improvements over tamoxifen.
  • Further clinical development is warranted for these promising therapies.
  • These agents represent a significant advancement in endocrine therapy for breast cancer.